Pierre Fabre Laboratories and RedRidge Bio ("RedRidge") today announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates ...

Other indications in rare diseases could also be developed by ValenzaBio. In parallel, Pierre Fabre is pursuing the development of its anti-IGF-1R ADC program (W0101) in oncology.

Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241 Provided by PR Newswire Jun 16, 2025, 1:00:00 AM ...

Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO ™ In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics CASTRES, France ...

Pierre Fabre is partnering with immunotherapeutics startup H-Immune to generate anticancer antibody candidates using the latter’s proprietary In Vitro Immunization (IVI) technology.